Methemoglobinemia With Dapsone Prophylaxis in a Patient With Minimal Change Disease
Copyright © 2022, Rovira Gonzalez et al..
Our case report represents the need to maintain vigilance for methemoglobinemia risk in patients without classic symptoms, specifically, in patients that develop shortness of breath after starting prophylaxis for Pneumocystis jiroveci pneumonia, mostly with dapsone. A case report of a 42-year-old male with minimal change disease nephrotic syndrome required Pneumocystis jiroveci pneumonia prophylaxis due to high-dose systemic steroids. The patient was started on dapsone due to side effects and the availability of alternative medications. Since starting therapy, the patient developed progressive dyspnea upon exertion for two weeks with intermittent hypoxia. The patient tested negative for glucose-6-phosphate dehydrogenase deficiency prior to starting dapsone. He was also on therapeutic enoxaparin due to a hypercoagulability state from nephrotic syndrome. The patient presented with hypoxia and dyspnea upon exertion, however, speaking in complete sentences and with no cyanosis or overt findings of hypervolemia. The patient remained hypoxemic despite supplemental oxygen. An arterial blood gas was performed and showed methemoglobin levels of 10.6 percent. He was treated with methylene blue with the resolution of methemoglobinemia and hypoxemia after a second dose. Trimethoprim-sulfamethoxazole was started for Pneumocystis jiroveci pneumonia prophylaxis. He was safely discharged home.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Cureus - 14(2022), 6 vom: 15. Juni, Seite e26393 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rovira Gonzalez, Manuel J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Case Reports |
|---|
| Anmerkungen: |
Date Revised 02.08.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.7759/cureus.26393 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344309894 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344309894 | ||
| 003 | DE-627 | ||
| 005 | 20231226022454.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7759/cureus.26393 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1147.xml |
| 035 | |a (DE-627)NLM344309894 | ||
| 035 | |a (NLM)35911303 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rovira Gonzalez, Manuel J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Methemoglobinemia With Dapsone Prophylaxis in a Patient With Minimal Change Disease |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.08.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2022, Rovira Gonzalez et al. | ||
| 520 | |a Our case report represents the need to maintain vigilance for methemoglobinemia risk in patients without classic symptoms, specifically, in patients that develop shortness of breath after starting prophylaxis for Pneumocystis jiroveci pneumonia, mostly with dapsone. A case report of a 42-year-old male with minimal change disease nephrotic syndrome required Pneumocystis jiroveci pneumonia prophylaxis due to high-dose systemic steroids. The patient was started on dapsone due to side effects and the availability of alternative medications. Since starting therapy, the patient developed progressive dyspnea upon exertion for two weeks with intermittent hypoxia. The patient tested negative for glucose-6-phosphate dehydrogenase deficiency prior to starting dapsone. He was also on therapeutic enoxaparin due to a hypercoagulability state from nephrotic syndrome. The patient presented with hypoxia and dyspnea upon exertion, however, speaking in complete sentences and with no cyanosis or overt findings of hypervolemia. The patient remained hypoxemic despite supplemental oxygen. An arterial blood gas was performed and showed methemoglobin levels of 10.6 percent. He was treated with methylene blue with the resolution of methemoglobinemia and hypoxemia after a second dose. Trimethoprim-sulfamethoxazole was started for Pneumocystis jiroveci pneumonia prophylaxis. He was safely discharged home | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a dapsone | |
| 650 | 4 | |a dyspnea | |
| 650 | 4 | |a hypoxemia | |
| 650 | 4 | |a methemoglobinemia | |
| 650 | 4 | |a methylene blue | |
| 650 | 4 | |a minimal change disease | |
| 650 | 4 | |a nephrotic syndrome | |
| 650 | 4 | |a pneumocystis jiroveci pneumonia prophylaxis | |
| 650 | 4 | |a shortness of breath | |
| 700 | 1 | |a Pargament, Robert |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cureus |d 2013 |g 14(2022), 6 vom: 15. Juni, Seite e26393 |w (DE-627)NLM24118083X |x 2168-8184 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2022 |g number:6 |g day:15 |g month:06 |g pages:e26393 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7759/cureus.26393 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2022 |e 6 |b 15 |c 06 |h e26393 | ||